Xenetic Biosciences, Inc. (NASDAQ:XBIO) | Finanzwire

Basculer en Français

9475	Companies
185452	Keywords
117801	Articles
99309	Press releases

Headlines Articles Press releases Xenetic Biosciences, Inc.

Home
Companies
Xenetic Biosciences, Inc.

BRIEF

published on 11/07/2024 at 15:05, 1 year ago

Xenetic Biosciences Extends Partnership with Scripps to Boost DNase Oncology Program

Cancer Treatment Research Collaboration CAR T-cell Therapy DNase Oncology Preclinical Development
PRESS RELEASE

published on 11/07/2024 at 15:00, 1 year ago

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Xenetic Biosciences extends Research Funding and Option Agreement with The Scripps Research Institute to advance DNase-based oncology program, targeting cancer with NETs via systemic DNase and CAR T-cell therapies

Xenetic Biosciences Cancer Treatment Research Funding DNase-based Oncology The Scripps Research Institute
BRIEF

published on 10/22/2024 at 14:50, 1 year 1 month ago

Xenetic Biosciences' Abstract Accepted for Presentation at SITC 2024

Xenetic Biosciences Cancer Treatment Immuno-oncology DNase Platform SITC 2024
PRESS RELEASE

published on 10/22/2024 at 14:45, 1 year 1 month ago

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
Xenetic Biosciences to present abstract at SITC 39th Annual Meeting on DNase I targeting Neutrophil Extracellular Traps for improved immune checkpoint blockade in CRC models

Xenetic Biosciences DNase I SITC 39th Annual Meeting Immuno-oncology Technologies Abstract Presentation
BRIEF

published on 10/17/2024 at 14:35, 1 year 1 month ago

Xenetic Biosciences Partners with Tokyo Medical University for Cancer Research

Xenetic Biosciences Cancer Research Ewing Sarcoma DNase I Tokyo Medical University
PRESS RELEASE

published on 10/17/2024 at 14:30, 1 year 1 month ago

Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform
Xenetic partners with Tokyo Medical University to evaluate recombinant DNase I for Ewing sarcoma treatment in preclinical model. Agreement enhances DNase program development

Xenetic Ewing Sarcoma Tokyo Medical University Recombinant DNase I Preclinical Model
BRIEF

published on 09/11/2024 at 15:05, 1 year 2 months ago

Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference

Xenetic Biosciences H.C. Wainwright Immune-oncology Investment Presentation Jim Parslow
PRESS RELEASE

published on 09/11/2024 at 15:00, 1 year 2 months ago

Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
Xenetic Biosciences presented at H.C. Wainwright 26th Annual Global Investment Conference. The biopharmaceutical company focuses on immune-oncology technologies for hard-to-treat cancers

Xenetic Biosciences Biopharmaceutical Immune-oncology JTC Team Cancers
BRIEF

published on 08/14/2024 at 14:05, 1 year 3 months ago

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Financial Results Clinical Development Biopharmaceutical Oncology Program Xenetic
PRESS RELEASE

published on 08/14/2024 at 14:00, 1 year 3 months ago

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. reports financial results for Q2 2024, focusing on DNase-based oncology program in preclinical studies with data due before year end. Ended quarter with $7.3M cash

Financial Results Xenetic Biosciences Cash Balance DNase-based Oncology Program Preclinical Studies

Accesswire

Published on 12/05/2025 at 02:35, 10 hours 59 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 11 hours 4 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 12 hours 34 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 14 hours 29 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 14 hours 34 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 13:00, 34 minutes ago

Zentra Group plc: Posting of Notice of Annual General Meeting
Published on 12/05/2025 at 13:00, 34 minutes ago

Form 8.3 - Zürcher Kantonalbank: Cicor Technologies Ltd.
Published on 12/05/2025 at 12:05, 1 hour 29 minutes ago

Cango Inc. Announces November 2025 Bitcoin Production and Mining Operations Update
Published on 12/05/2025 at 12:00, 1 hour 34 minutes ago

CGTN：Strengthening cultural ties: Peng Liyuan, Brigitte Macron visit Beijing People's Art Theatre
Published on 12/05/2025 at 12:00, 1 hour 34 minutes ago

Iute Group: Successful Issue of Additional EUR 2025/2030 Bonds – Circulating Volume Increased to EUR 160 Million

Les Echos

Published on 12/05/2025 at 08:45, 4 hours 49 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 19 hours 34 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 19 hours 49 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 19 hours 50 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 6 hours ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

View all LES ECHOS COMFI WIRE